Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,557.12 +294.10 (+0.44%) CMC Crypto 200
1,380.83 -37.04 (-2.61%)
PTN Jul 2024 2.500 call
| Previous close | 0.2000 |
| Open | 0.1000 |
| Bid | 0.1000 |
| Ask | 0.3000 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 559 |
PR NewswirePalatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate the safety and efficacy of bremelanotide, a melanocortin 4 receptor (MC4R) agonist, co-administered with tirzepatide (GLP-1/GIP) in obese patients. The primary endpo
ZacksPalatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
Palatin Technologies (PTN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GuruFocus.com
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ...
Despite a dip in product sales, PTN progresses in clinical developments and maintains a stable financial footing.
